Grace Taylor, MS, MA

News
The Impact of Lower Cost Alternatives or Biosimilars on The Cost of Key Cancer Drugs
10/28/2023
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and colleagues examined the impact of lower cost alternative drugs or biosimilars on the cost of key cancer drugs.
Puneeth Indurlal, MD, MS, and...
10/28/2023
Journal of Clinical Pathways
News
Analysis of Symptom Improvements in Patients With MF Receiving Momelotinib in the SIMPLIFY Studies
09/19/2023
Ruben A. Mesa, DO, and colleagues analyzed changes in total symptom scores and individual symptom scores of patients with myelofibrosis who participated in the SIMPLIFY-1 and SIMPLIFY-2 studies.
Ruben A. Mesa, DO, and colleagues analyzed changes in total symptom scores and individual symptom scores of patients with myelofibrosis who participated in the SIMPLIFY-1 and SIMPLIFY-2 studies.
Ruben A. Mesa, DO, and...
09/19/2023
Journal of Clinical Pathways
News
Treatment Patterns and Overall Survival for Patients With Metastatic Urothelial Carcinoma Following FDA Approval of Avelumab Maintenance Therapy
02/15/2024
A study by Haojie Li, MD, PhD, and colleagues evaluated real-world treatment patterns and overall survival for patients with mUC during the period between the approval of maintA and P+EV for use in the US.
A study by Haojie Li, MD, PhD, and colleagues evaluated real-world treatment patterns and overall survival for patients with mUC during the period between the approval of maintA and P+EV for use in the US.
A study by Haojie Li, MD, PhD,...
02/15/2024
Journal of Clinical Pathways
News
Phase 3 KEYNOTE-522 Trial Meets Overall Survival Endpoints in Patients With TNBC
05/30/2024
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase...
05/30/2024
Journal of Clinical Pathways
News
Analysis of Patient-Reported Outcomes of Patients With MF or ET in the MOST Study
04/28/2023
Ellen Ritchie, MD, Weill Cornell Medical College, New York, NY, and colleagues recently analyzed patient-reported outcomes (PROs) in myelofibrosis or essential thrombocythemia for patients who participated in the MOST study to measure symptom...
Ellen Ritchie, MD, Weill Cornell Medical College, New York, NY, and colleagues recently analyzed patient-reported outcomes (PROs) in myelofibrosis or essential thrombocythemia for patients who participated in the MOST study to measure symptom...
Ellen Ritchie, MD, Weill Cornell...
04/28/2023
Journal of Clinical Pathways
News
Using Mindfulness-Based Intervention to Improve Fatigue, Mood Challenges in Adolescents With Neuroimmune Disease
05/28/2024
Study examines the effectiveness of the Learning to BREATHE mindfulness-based intervention in improving fatigue and mood challenges in a adolescent population with neuroimmune disease.
Study examines the effectiveness of the Learning to BREATHE mindfulness-based intervention in improving fatigue and mood challenges in a adolescent population with neuroimmune disease.
Study examines the effectiveness...
05/28/2024
First Report Managed Care
News
The Impact of Dosing Approaches for Lenalidomide on Total Cost of Care
10/27/2023
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US Oncology Network, McKesson, The Woodlands, Texas, and colleagues investigated the impact of different dosing approaches of lenalidomide on the total cost of care for patients in The US Oncology Network.
Puneeth Indurlal, MD, MS, The US...
10/27/2023
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways
News
Survival Benefits of Carboplatin Plus Paclitaxel and Immunotherapy in Patients With Advanced Endometrial Cancer
11/29/2023
Shannon Westin, MD, and colleagues analyze the results from the phase 3 DUO-E trial, which examined the effectiveness of immunotherapy + carboplatin/paclitaxel on progression-free survival for patients with endometrial cancer.
Shannon Westin, MD, and colleagues analyze the results from the phase 3 DUO-E trial, which examined the effectiveness of immunotherapy + carboplatin/paclitaxel on progression-free survival for patients with endometrial cancer.
Shannon Westin, MD, and...
11/29/2023
Journal of Clinical Pathways
AI
News
The Potential for AI in Oncology
04/11/2024
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay...
04/11/2024
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use